Prevalence, treatment, and control of dyslipidemia and hypertension in 4278 hiv outpatients

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 4, 2014, Pages 370-377

  Myerson, Merle ^a,b   Poltavskiy, Eduard ^c   Armstrong, Ehrin J ^d   Kim, Shari ^b   Sharp, Victoria ^b   Bang, Heejung ^c  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b MOUNT SINAI HEALTH SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; ANTIHYPERTENSIVE AGENTS; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; OUTPATIENTS; PREVALENCE; RISK FACTORS;

EID: 84903772474     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000168     Document Type: Article

References (18)

1. Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008;118:198-210
2. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118:e29-e35
3. Friis-Moller N, Thiebaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010; 17:491-501
4. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and non-fasting lipid levels. Circulation. 2008;118:2047-2056
5. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502
6. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421
7. Goff DC Jr, Bertoni AG, Kramer H, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation. 2006;113:647-656
8. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560- 2572. (Pubitemid 37430158)
9. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. National Institutes of Health. Obes Res. 1998;6(suppl 2):51S-209S
10. Reinsch N, Neuhaus K, Esser S, et al. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART Study. Eur J Prev Cardiol. 2012;19:267-274
11. Baekken M, Os I, Sandvik L, et al. Hypertension in an urban HIVpositive population compared with the general population: influence of combination antiretroviral therapy. J Hypertens. 2008;26:2126-2133
12. Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58:1-10
13. Parra S, Coll B, Aragones G, et al. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Med. 2010;4:225-231
14. Gu Q, Burt VL, Dillon CF, et al. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension. Circulation. 2012;126:2105-2114
15. Angell SY, Garg RK, Gwynn RC, et al. Prevalence, awareness, treatment, and predictors of control of hypertension in New York City. Circ Cardiovasc Qual Outcomes. 2008;1:46-53
16. Seaberg EC, Munoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19:953-960. (Pubitemid 40834939)
17. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitorsparing regimens for initial HIV treatment. AIDS. 2009;23:1109-1118
18. Medina-Torne S, Ganesan A, Barahona I, et al. Hypertension is common among HIV-infected persons, but not associated with HAART. J Int Assoc Physicians AIDS Care (Chic). 2012;11:20-25